Mylan Pushes Back Against EpiPen Buyers' Appeal Bid
By Khorri Atkinson (September 8, 2021, 10:15 PM EDT) -- Mylan urged a Kansas federal judge to dismiss a class of EpiPen buyers' bid to appeal a June order finding that the drug giant cannot face racketeering allegations or claims over rebates for its allergy treatment, arguing that they're simply attempting to relitigate issues the trial court already examined.
Mylan asserted in an opposition brief Tuesday that U.S. District Judge Daniel D. Crabtree's ruling partially granting the company's summary judgment motion doesn't need appellate review because the buyers failed to show their interlocutory appeal would ultimately end the case or eliminate the need for a jury trial currently set to begin in...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!